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Cytoadhesion of Plasmodium falciparum infected erythrocytes (IEs) to the endothelial lining of 
blood vessels protects parasites from splenic destruction, but also leads to detrimental 
inflammation and vessel occlusion. Surface display of the P. falciparum erythrocyte membrane 
protein 1 (PfEMP1) adhesion ligands exposes them to host antibodies and serum proteins. 
PfEMP1 are important targets of acquired immunity to malaria, and through evolution, the 
protein family has expanded and diversified to bind a select set of host receptors through 
antigenically diversified receptor-binding domains. Here, we show that complement component 
1s (C1s) in serum, cleaves PfEMP1 at semi-conserved arginine motifs located at interdomain 
regions between the receptor-binding domains, rendering the IE incapable of binding the two 
main PfEMP1 receptors, CD36 and endothelial protein C receptor (EPCR). Bioinformatic 
analyses of PfEMP1 protein sequences from 15 P. falciparum genomes found the C1s motif was 
present in most PfEMP1 variants. Prediction of C1s cleavage and loss of binding to endothelial 
receptors was further corroborated by testing of several different parasite lines. These 
observations suggest that the parasites have maintained susceptibility for cleavage by the serine 
protease, C1s, and provides evidence for a complex relationship between the complement system 




Mature asexual stages of Plasmodium falciparum-infected erythrocytes (IEs) bind to 
endothelium to avoid splenic clearance. The PfEMP1 family is the major cytoadhesion ligand at 
the IE surface and is essential for parasite sequestration. In this study, we show that complement 
component 1s (C1s), found in serum, cleaves PfEMP1 on the IEs to prevent binding to 
endothelial cells. We find that the C1s cleavage sites are maintained at semi-conserved arginine 
motifs located at interdomain regions between PfEMP1 receptor-binding domains and upstream 
of the transmembrane region. This suggests that parasites have taken advantage of a human 
serum protease, either to escape antibody recognition of sequestered parasites or to dampen 







Plasmodium falciparum is the most virulent Plasmodium spp., causing the most deaths 
from malarial parasites (1). This virulence is largely due to the parasite´s ability to invade all 
ages of erythrocytes and its binding to the endothelium. In their late stages, infected erythrocytes 
(IEs) attach to endothelial cells to escape blood circulation and the killing mechanisms in the 
spleen (2). The sequestration of IEs in host organs reduces blood flow and promotes 
coagulopathy, inflammation and vascular leakage (3, 4). In severe infections, sequestration of 
parasites in the brain may cause breakdown of the blood brain barrier and cerebral edema leading 
to death or neurologic sequelae to those who survive (2, 5-7).  
IE sequestration is mediated by members of the P. falciparum erythrocyte membrane 
protein 1 (PfEMP1) family (8-10), which are exported to the IE surface where they bind specific 
endothelial receptors. PfEMP1 are single-pass membrane proteins, with the intracellular acidic 
terminal segment (ATS) anchored in the erythrocyte membrane by intracellular parasite and host 
cytoskeleton proteins. The PfEMP1 extracellular region can vary in size from 200-500 kDa by 
the number and type of different receptor binding Duffy binding-like (DBL) and cysteine rich-
interdomain region (CIDR) domains (11). Despite varying in sequence, all PfEMP1 contain an 
N-terminal DBLα-CIDR domain complex, termed the head structure, which segregates the 
protein family into a few mutually exclusive binding phenotypes (as reviewed in (12)). Thus, 
most PfEMP1 bind either endothelial protein C receptor (EPCR) via their CIDRα1 domain or 
CD36 via their CIDRα2-6 domain, and a minority of PfEMP1 head structures have CIDRβ, γ or 
δ domain types with unknown binding specificity (12). The head structure can be followed by 
two to seven additional domains. The function of the PfEMP1’s C-terminal domains is not fully 
resolved; however, some bind leukocyte adhesion receptors ICAM-1 (via the DBLβ domain) 
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(13), platelet endothelial cell adhesion molecule (PECAM1) (14), integrin αVβ3 (15) or 
hyaluronan‐binding protein 1 (HABP1) (16). Other domains have been found to bind serum 
proteins, non-immune IgG (17) and IgM (18) and α2-macroglobulin (19), facilitating 
cytoadherence to uninfected erythrocytes (rosetting) and escape from antibody or complement 
recognition (20). The exception to these rules is the VAR2CSA PfEMP1 variant, which is 
defined by six tightly connected and unique DBL domains, which form a single multi-domain 
complex to bind placental chondroitin sulphate A (CSA) (21). Whereas multiple adhesion 
properties have been mapped to PfEMP1 adhesion domains, less attention has been placed on the 
interdomain regions, which are characterized by aspartic acid and glutamic acid-rich regions and 
proline residues, but some also contain conserved motifs (11). The interdomain regions have 
been thought to function as spacers between the adhesion domains, and a function has not been 
ascribed to the conserved motifs.   
Each parasite genome encodes ~60 PfEMP1 variants, but only one PfEMP1 will be 
expressed by each individual parasite. PfEMP1 are key targets of acquired immunity to malaria. 
Expression of one of many variants among parasites released from the liver (22), and the ability 
to switch PfEMP1 expression at each blood stage cycle, provides the parasite optimal chances of 
survival regardless of the immune status of the host (8). The PfEMP1 binding phenotypes are 
linked to clinical outcome of infection. VAR2CSA-mediated sequestration in the placenta is the 
cause of severe malaria in pregnancy (23, 24), whereas parasites expressing EPCR-binding 
PfEMP1 is associated with severe malaria pathogenesis in non-immune individuals, and parasites 
expressing CD36-binding PfEMP1 appear to be linked to uncomplicated infections in semi-
immune individuals (25-33).  
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Pathogens that live in human serum have frequently evolved mechanisms to evade 
complement-mediated lysis. Expanding literature on complement and malarial parasites is 
reviewed by Kennedy et al. (34). For example, there is evidence that P. falciparum merozoites 
acquire C1 esterase inhibitor during red blood cell invasion to control complement activation 
(35). The present study was initiated to explain the loss of IE binding to EPCR after exposure to 
human sera or human plasma from malaria naïve people, but not to bovine sera (30). Previous 
work suggested the inhibitory serum component(s) was neither albumin nor IgM, and the 
inhibitory activity persisted after IgG depletion from serum (30). We now show that the serum 
component, complement 1s (C1s) cleaves PfEMP1 on IEs to prevent adherence of either EPCR 
or CD36-binding PfEMP1 subsets. We identify C1s cleavage sites at conserved motifs in 
PfEMP1 located in the unstructured interdomain regions between DBL and CIDR domains but 
not in VAR2CSA. Using a panel of parasite lines expressing different PfEMP1 variants that did 
or did not contain the predicted cleavage motif, we were able to demonstrate that binding to 
endothelial receptors was largely affected in those predicted for cleavage. Unlike the free IEs, 




C1s cleavage of IT4var19 PfEMP1 inhibits IE binding to EPCR  
To identify the serum factor responsible for inhibiting the EPCR-dependent endothelial 
cell binding of IEs expressing the IT4var19 PfEMP1 variant (30), IgG-depleted serum was 
separated by size exclusion chromatography into 25 fractions. Two serum fractions, B11 and C3, 
significantly inhibited binding of P. falciparum IT4var19 IEs to a human brain endothelial cell 
line (Fig. 1A and 1B). Serum proteins in the inhibitory fractions B11 and C3 were identified by 
MS/MS (Dataset S1) and compared to fractions B9, C1 and C5 eluted before and after the 
inhibitory fractions. Eight proteins (attractin, C1s, complement component 4b (C4b), 
complement factor H, IgD, inter-alpha-trypsin inhibitor heavy chain H1 (IT1H1) and H2 (ITIH2) 
and kappa light chain) were identified as being unique to both inhibitory fractions and absent in 
non-inhibitory fractions B9, C1, and C5. Of these, only the serine protease C1s (36) significantly 
inhibited IT4var19 IE binding to endothelial cells (Fig. 1C). Also, C1s inhibited IT4var19 IE-
EPCR binding in a concentration dependent manner, with significant binding inhibition at 
physiological concentration of C1s in serum, 30 μg/mL (37, 38), and no significant inhibitory 
effect at 3 μg/mL C1s and below (Fig. 2A). 
C1s cleavage of arginine-specific bonds in the complement components C2 and C4 is a 
central process in initiating the proteolytic cascade of the classical complement pathway (39). 
However, several other human non-complement proteins, including MHC class I, are processed 
by C1s (40, 41), suggesting a broader function of C1s. The peptide substrate specificity of C1s 
has been described as [A/S/T][G/V/L][G/A]R‖[A/S/V/L] L[G/V/L/R] (39). Of interest, the serine 
protease thrombin has previously been found to cleave native IT4var19, possibly at a C1s-like 
motif sequence GLGR‖SL located in the interdomain region between the DBLγ and DBLδ 
  8
domains based on thrombin cleavage of IT4var19-derived peptides (42). This study also found 
thrombin could detach IT4var19 IEs already adherent to human lung microvascular endothelial 
cells. To test C1s reversal of IT4var19 IEs bound to recombinant EPCR, high concentrations of 
C1s (30, 50 or 100 μg/mL) was added to EPCR-bound IT4var19 IEs but binding to EPCR could 
not be reversed (Fig. 2B). 
To determine if C1s cleaved the IT4var19 PfEMP1 on the IE surface, IEs were incubated 
with recombinant C1s. Unlike untreated parasites that showed PfEMP1 antibody staining on the 
IE surface (Fig. 3A), C1s-treated IEs showed no PfEMP1 staining when stained with an antibody 
to the N-terminal DBL region of IT4var19 (Fig. 3B). C1s treatment did not affect IE surface 
detection of VAR2CSA expressing IEs (Fig. 3C and 3D). Together, these observations suggest 
that C1s cleaves the IT4var19 PfEMP1 variant.  
 
C1s cleaves other PfEMP1 at serine protease motifs in spacer regions separating receptor-
binding domains 
To further explore and map the C1s cleavage site in PfEMP1 variants, we tested two 
different PfEMP1 variants where we had clonal parasite lines and matching full-length 
recombinant ectodomains. The IT4var20 PfEMP1 represents an EPCR binding variant and the 
IT4var13 represents a dual CD36 and ICAM-1 binding variant. C1s abrogated parasite binding to 
EPCR and CD36, respectively, whereas ICAM-1 binding by IT4var13 IEs was retained (Fig. 4A 
and 4B). Quantitative PCR confirmed that ITvar20 and ITvar13 transcripts were dominant 
among expressed IT4 var genes in the IT4var20 and IT4var13 parasite lines, respectively (Fig. 
4C). This indicated that both types of PfEMP1 variants were susceptible to C1s cleavage, but 
C1s cleavage of IT4var13 had occurred between the CD36 and ICAM-1 binding domains.  
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To precisely map the cleavage site, recombinant proteins derived from the full-length 
ectodomain sequences of the IT4var20 (287 kDa) and IT4var13 (312 kDa) were treated with 50 
nM C1s at a 1:1 ratio. C1s cleaved both proteins into two major products (Fig. 5A). Mass 
spectrometry and N-terminal protein sequencing analysis of these products revealed that C1s 
cleaved IT4var20 at three closely spaced C1s-like motifs located in the interdomain region 
between the DBLγ and DBLδ domains (Fig. 5B and Dataset S2). Similarly, the IT4var13 
recombinant protein was cleaved at a C1s-like motif located in a shorter 23-amino acid 
interdomain region between the DBLαCIDRα head structure and the adjacent DBLβ domain 
(Fig. 5B).  
In contrast to full-length recombinant ectodomains, C1s treatment of recombinant 
PfEMP1 protein spanning the N-terminal head structure (NTS-DBLαCIDRα) of the IT4var20 
and the PFD1235w PfEMP1 variants, or single CIDR domains binding EPCR (IT4var19 
CIDRα1) or CD36 (IT4var26 CIDRα3) did not result in cleavage (Fig. 6A). Moreover, the 
recombinant head structure proteins as well as the cleavage products of the full ectodomains 
retained their receptor binding activity following C1s treatment (Fig. 6B). These results aligned 
with the observed loss of EPCR binding for IEs expressing IT4var20, and with the loss of CD36 
but not ICAM-1 binding for IT4var13-expressing IEs, demonstrating that C1s cleaved at C1s 
serine protease-like sites located in interdomain regions of diverse PfEMP1 variants. 
 
C1s cleavage motifs are conserved in the interdomain regions of PfEMP1 
Previous work has not identified a function for the interdomain regions in PfEMP1 
variants (43), although some contain semi-conserved sequence motifs, also termed homology 
blocks (HBs) (11).  Remarkably, three homology blocks that specifically map to the interdomain 
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regions (HB49, HB134 and HB241) each contain a conserved arginine residue and bear striking 
resemblance to the canonical C1s cleavage motif (MEROPS - the Peptidase Database 
(ebi.ac.uk)), and overlapped the observed C1s cleavage sites in IT4var13 and IT4var20 
recombinant ectodomains (Fig. 5C). Notably HB49, HB134 and HB241 are all specific to the 
PfEMP1 interdomain regions.  
Since the original definition of PfEMP1 HBs from the reference 3D7 genotype and six 
partial parasite genomes (11), the full-length PfEMP1 ectodomain sequences have been validated 
from additional P. falciparum genomes using long read sequencing (44). To update the 
homology blocks, we extracted all interdomain regions from a total of 15 parasite genomes and 
redefined re-occurring sequence motifs using the MEME tool (45). This approach identified two 
partially overlapping motifs (MEME1 and 2) overlapping 90% of sequences previously 
annotated by HB49, HB134 and HB241. Mapping these putative C1s cleavage sites back onto 
the domain-annotated and aligned PfEMP1 sequences revealed a striking pattern of proposed 
C1s sites located predominantly mid-PfEMP1 across the protein family and/or upstream of the 
transmembrane region (Fig. 5D). Overall, 80% of PfEMP1 carried one or more C1s sites with no 
association to particular PfEMP1 subsets (Fig. 5D), apart from the lack of C1s sites in 
VAR2CSA and the short unusual VAR3 PfEMP1. 
To experimentally validate the bioinformatic predictions of C1s cleavage sites, an 
additional eight available parasite lines representing EPCR, CD36 or ICAM-1 binding 
phenotypes were exposed to C1s treatment (Table 1). This showed either no effect or loss of 
receptor binding in accordance with predicted C1s cleavage sites of the expressed PfEMP1 




 To avoid splenic destruction, P. falciparum-IEs sequester in the microcirculation. The 
sequestration phenotype exposes the PfEMP1 adhesion ligands to both antibodies and serum 
proteins. Unexpectedly, we discovered that most PfEMP1 molecules harbor semi-conserved 
arginine sequence motifs accessible to serine protease C1s cleavage. The C1s cleavage sites are 
located in the interdomain region, which are characterized by aspartic acid and glutamic acid-
rich regions and thought to function as a spacer between receptor-binding domains. C1s cleavage 
did not directly affect the DBL and CIDR adhesion domains but did render IEs unable to bind 
receptors due to loss of functional PfEMP1 domains.  
 In humans, C1s is present in plasma as a pro-enzyme and has a restricted substrate 
specificity after activation including its key targets C2 and C4 of the complement cascade (40, 
46). In addition, several non-complement substrates for activated C1s have been described, 
including MHC class I and insulin-like growth factor binding protein 5b (36, 40, 41, 47). 
However, C1s is able to cleave a broad range of unfolded peptides with semi-constrained 
sequence motifs (39). Here, we found PfEMP1 was cleaved at sites matching previously defined 
C1s cleavage sites (39), as well as at closely related motifs. These motifs are common in 
PfEMP1 variants, located within the interdomain sequence regions, and are particularly enriched 
upstream of the DBLδ domains in the mid-PfEMP1 regions. Interdomain regions can span up to 
200 amino acids and consist mainly of low-complexity runs of proline and acidic aspartic acid 
and glutamic acid residues (11), broken up by the more distinct C1s-like motifs. This 
organization predicts a disordered structure, which along with sequence diversity of the C1s-like 
motifs may prevent antibody recognition. More importantly, its organization may ensure that the 
residues in the C1s motifs are unfolded and accessible to cleavage. This notion aligns with the 
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recent Cryo-EM resolution of the full-length VAR2CSA ectodomain (21) showing that its 
interdomain regions play central roles in folding the quaternary structure of the six-domain large 
complex required for protein-glycan binding.  
Importantly, the abundance and position of the C1s motifs in PfEMP1, strongly suggest 
that they have been retained in this fast-evolving and highly recombinogenic gene family 
because they provide the parasite a selective advantage. Thus, P. falciparum appears to have 
adapted cleavage by C1s or indeed other serine proteases, such as thrombin (42), to secure 
optimal control of its endothelial sequestration process. Further studies will be necessary to 
determine if other serine proteases in serum, including those of the complement and coagulation 
cascades, the membrane-anchored serine proteases (48), or even P. falciparum derived serine 
proteases cleave PfEMP1 from the red blood cell membrane. 
To sequester in the microcirculation, P. falciparum-IEs are exposed to serum proteins. 
The physiological relevance of the findings reported here is not easily resolved by in vitro 
experiments with their limited resemblance of the human vascular environment. A specific C1s-
inhibitor would be important to test, but none exist. However, our study does indicate that the 
C1s-like sites in PfEMP1 are accessible to serine protease cleavage in vitro. Whether such 
proteolytic cleavage of PfEMP1 occurs in vivo is a key question raised by our data. The 
complement cascade is under tight regulation to avoid consumption of complement proteins and 
activated C1s would usually be inhibited by C1 esterase inhibitor. During malaria infection, 
complement is activated (49, 50) and complement regulatory proteins are depleted (49, 51, 52). 
Therefore, PfEMP1 proteins at the IE surface may be exposed to activated serine proteases, such 
as complement C1s and thrombin, which then cleave PfEMP1 and interfere with cytoadhesion in 
vivo. As complement and coagulation pathways are likely to be more active during high burden 
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parasite infections, we hypothesize that the extent of PfEMP1 cleavage will be influenced by 
local concentrations of serine proteases. 
We propose two hypothetical mechanisms explaining the conserved C1s cleavage of 
PfEMP1. First, it is possible that PfEMP1 cleavage serves as an immune escape mechanism in 
which antibody-opsonized PfEMP1 molecules are released to avoid killing of early trophozoite-
stage IEs passing through the spleen or to avoid opsonization of adherent IE by inflammatory 
cells, such as NK cells (53) or infiltrating monocytes in peripheral blood vessels. The latter 
scenario aligns with the finding that C1s did not release bound IE and that some C-terminal 
PfEMP1 DBLε and DBLζ domains, which typically would remain on the IE following C1s 
cleavage, bind serum proteins α2-macroglobulin and non-immune IgG, IgM to shield the IE from 
complement or antibody mediated opsonization (17-20). Secondly, and as previously suggested, 
cleavage by C1s or other serine proteases such as thrombin may act as a “steam valve” 
mechanism to dampen IE sequestration efficiency in hosts with uncontrolled systemic 
inflammation (3) threatening survival of the host and parasite. In support of this theory, Gillrie et 
al. found thrombin to release adherent IEs (42); however, in the one case studied, C1s did not 
release adherent IEs. 
Various studies have shown decreased serum activity and levels of complement 
components in malaria, including C1q which together with a C1s2-C1r2 tetramer forms the Ca2+-
dependent C1 complex (37, 54-57). It is possible that reduction in C1s during malaria infection 
modulates PfEMP1 function. Future studies to assess plasma levels of activated C1s in malaria 
patients should be possible, and suggestions that proteases could be used therapeutically to 
reverse sequestration (42) could be explored.  
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We have described a new and unexpected aspect of the endless battle for survival 
between the malaria parasite and its host. A better understanding of the role of C1s in the 
pathogenesis of malaria is needed to determine if it may protect from most severe disease by 
cleaving PfEMP1 and reducing cytoadhesion or whether C1s and other serum proteases have 
been hijacked by the parasite to escape immune attack. 
 
Materials and Methods 
Parasite and brain endothelial cell culture  
IT4 parasites that predominantly express IT4var19 PfEMP1 (27, 30) were kept in 
continuous culture with O+ human red blood cells (Interstate Blood Bank, Memphis, TN) at 2% 
hematocrit in Roswell Park Memorial Institute medium (RPMI) 1640 (CUS-0645; KD Medical, 
Columbia, MD) supplemented with 0.25% albumax (11021; Thermo Fisher Scientific, San Jose, 
CA), 5% pooled human serum (Interstate Blood Bank, Memphis, TN), 50 µg/mL gentamicin 
(KD Medical, Columbia, MD) and 2.0 g/L sodium bicarbonate (KD Medical, Columbia, MD). 
FCR3-CSA parasites (predominantly expressing VAR2CSA PfEMP1), 3G8 (IT4var1) (58), ItG 
ICAM-1 (IT4var16) (58), P6G2 (IT4var31) (58), P2E11 (IT4var33) (58), P6D12 (IT4var39/67) 
(58), and 3173-S parasites predominantly expressing an EPCR-binding PfEMP1 (59) were 
cultured in RPMI 1640 supplemented with 0.5% albumax, 50 µg/mL gentamicin and 2.0 g/L 
sodium bicarbonate. Parasite lines derived from the IT4 parasite genotype predominantly 
expressing IT4var20 or IT4var13 or from the genome reference 3D7 parasite genotype 
(predominantly expressing MAL6P1.316) were cultured in RPMI 1640 supplemented with 0.5% 
albumax, 4 mM L-glutamine (G7513; Sigma-Aldrich, St. Louis, MO), and 50 µg/mL gentamicin 
(G1272; Sigma-Aldrich, St. Louis, MO) with PfEMP1-expression maintained by alternate 
antibody selection using rat anti-rIT4VAR20/rIT4var13 antibodies and panning on HBMEC 
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(IT4var20) or CHO-ICAM-1 cells (IT4var13), respectively as previously described (29). For the 
IT4var20 and IT4var13 parasite lines, analysis of var gene expression was done by quantitative 
PCR as previously described (60). All parasite lines were cultured in 5% O2, 5% CO2 and 90% N 
gas mixture with the exception of 3173-S parasites (cultured in 1% O2, 5% CO2 and 94% N gas 
mixture) and IT4var13 and IT4var20, which were cultured in 2% O2, 5.5% CO2 and 92.5% N gas 
mixture.  
Human brain endothelial cells, HBEC-5i (ATCC® CRL-3245™; ATCC, Manassas, VA) 
cells were cultured as previously described (61). Briefly, the cells were cultured on 0.1% gelatin 
coated tissue flask in Dulbecco’s Modified Eagle’s Medium (DMEM)/ Nutrient Mixture F-12 
medium (D6421; Sigma-Aldrich, St. Louis, MO) supplemented with 2 mM L-glutamine 
(A2916801; ThermoFisher Scientific, San Jose, CA), 100 U/mL penicillin/0.1 mg/mL 
streptomycin (15140122; ThermoFisher Scientific, San Jose, CA), 10% v/v heat-inactivated fetal 
bovine serum, HI-FBS (16140071; ThermoFisher Scientific, San Jose, CA) and 1% v/v 
endothelial cell growth supplement (1052; ScienCell, Carlsbad, CA), pH 7.4 at 37°C in 5% CO2.  
 
IE adhesion assays to endothelial cells 
IE binding to a human brain endothelial cell line, HBEC-5i, was done as previously 
described (30). Briefly, 2% hematocrit of gelatin purified mature trophozoite-stage IEs in 
DMEM binding medium [bicarbonate-free DMEM/Nutrient Mixture F-12 Ham (D8900; Sigma-
Aldrich, St. Louis, MO), supplemented with 2 mM L-glutamine and 100 U/mL penicillin/0.1 
mg/mL streptomycin, pH 7.3] were co-incubated with confluent HBEC-5i in 48-well plates at 37 
°C for 75 mins with gentle rocking of the plate every 30 mins. Unbound IEs were washed off and 
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the bound cells were fixed with 2% glutaraldehyde and stained with 5% Giemsa. The cells were 
counted at 40x with a Zeiss Axio Vert A1 inverted microscope (Zeiss, Oberkochen, Germany).  
For binding inhibition assays, serum and serum fractions (at 10%), recombinant human 
attractin (7238-AT-050; Novus Biologicals, Centennial, CO), C1s (A104; Complement 
Technology, Tyler, TX or 2060-SE; R&D Systems, Minneapolis, MN), human complement C4b 
(H00000721-Q01; Novus Biologicals, Centennial, CO), human complement factor H 
(H00003075-P03; Novus Biologicals, Centennial, CO), IgD (NB100-62667; Novus Biologicals, 
Centennial, CO), human kappa light chain (H00003514-P01; Novus Biologicals, Centennial, 
CO), human inter-alpha-trypsin inhibitor heavy chain H1 (IT1H1) (H00003697-P01; Novus 
Biologicals, Centennial, CO) and H2 (ITIH2) (NBP2-31750PEP; Novus Biologicals, Centennial, 
CO) (at physiological concentrations in serum, ⁓10% of the physiological concentrations or an 
estimated concentration where serum levels could not be found, Table S1) were added to the 
parasites in DMEM binding medium immediately before co-incubation with HBEC-5i.  
 
IE adhesion assays to receptor molecules immobilized on plastic 
The receptor-binding assays were conducted as previously described (30). Plastic plates 
were spotted with 5 µL of EPCR (13320-H02H; Sino Biologicals, Wayne, PA), CSA (a gift from 
Dr. Michal Fried), CD36 (1955-CD; R&D Systems, Minneapolis, MN) or ICAM-1 (720-IC; 
R&D Systems, Minneapolis, MN); all recombinant proteins, except for ICAM-1 which was used 
at 100 µg/mL, were at a concentration of 50 µg/mL. PBS acted as the negative control. Plates 
were incubated at 4C overnight in a humidified box, after which they were blocked with 3% 
BSA in PBS for 2 h at 37C. After blocking, a liquid blocker super PAP pen (71312; Electron 
Microscopy Sciences, Hatfield, PA) was used to draw circles around each spot to ensure that 
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parasite suspensions with differing concentrations of C1s were contained and did not leak onto 
other spots. Gelatin-enriched IEs were suspended at 2% hematocrit in binding medium 
(bicarbonate-free DMEM-F12 Ham (D8900; Sigma)/0.1% BSA, pH 7.2-7.4). Parasites were 
incubated with or without the desired concentration of C1s (0.03 µg/mL – 30 µg/mL) for 30 
mins at 37C. Subsequently, the parasites were added to the appropriate spots and incubated for 
1 h at 37C, with resuspension every 12 mins by gently swirling the dish. Unbound IEs were 
washed off with binding medium, whilst adherent cells were fixed with 2% glutaraldehyde for 1 
h and stained with 5% Giemsa for 10 min. Bound IEs were counted by light microscopy with a 
40x objective, with three fields being counted per spot.  
Static binding assay for IT4var20 IEs and IT4var13 IEs were as previously described 
(62). Briefly, late trophozoite and schizont stages were purified using Magnetic Cell Sorting 
(MACS, Miltenyi Biotec, Germany), and adjusted to 4 x 106 cells/mL in 2% FCS (in PBS). 
Parasites were pre-incubated 1 h with or without 100 µg/mL of rC1s (204879; Sigma-Aldrich, 
St. Louis, MO) before being added to petri dishes (BD Falcon 351029) coated with spots of 20 
µL of 20 µg/mL rEPCR (63), CD36 (SRP6378; Sigma-Aldrich, St. Louis, MO), ICAM-1 (64) or 
2% BSA (A7030; Sigma-Aldrich, St. Louis, MO). After one hour of incubation at 37°C, 
unbound parasites were washed away, while bound parasites were fixed with glutaraldehyde, 
stained with Giemsa and counted. 
For assays investigating the reversal of IE bound to EPCR or CSA, the receptor-binding 
portion was conducted as stated above; however, spots were incubated with the parasite 
suspension for 45 mins at 37C. After washing of unbound IEs with binding medium, C1s (30 
µg/mL – 100 µg/mL) in binding medium was added to the appropriate spot and incubated at 
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37C for another 45 mins. The spots were then gently washed with binding medium and bound 
IEs were fixed, stained, and counted as described above.  
 
C1s treatment of IEs and immunofluorescent assay 
Gelatin-purified IT4var19 and FCR3 pigmented trophozoite-stage IEs were washed twice 
with RPMI and treated with 100 nM (8 µg/mL) C1s at 2% hematocrit in RPMI at 37°C for 2 hrs. 
IEs in RPMI only with no C1s were included as controls. The IT4var19 and FCR3 IEs were 
washed three times with PBS and stained with 25 µg/mL anti-IT4var19 NTS.DBLα rabbit IgG 
(27) and anti-FCR3VAR2CSA (full length) rat IgG diluted in 1% BSA/PBS, respectively. A “no 
antibody” control was included with both parasite lines. The parasites were incubated at 4°C for 
1 hr, washed three times in PBS and stained with a 1:500 dilution of Alexa Fluor 488 goat anti-
rabbit IgG (A-11008; Life Technologies, Carlsbad, CA) or Alexa Fluor 594 goat anti-rat IgG (A-
11007 Invitrogen, Carlsbad, CA) in PBS/1% BSA at 4°C for 45 mins. The parasites were washed 
three times in PBS, smeared onto glass slides and air dried. The slides were mounted in ProLong 
Gold Antifade Mountant with DAPI (P36935; Invitrogen, Carlsbad, CA), covered with cover 
slips and sealed with Cytoseal-60 (8310-4; ThermoFisher Scientific, San Jose, CA). The cells 
were viewed using a Zeiss laser scanning microscope (LSM) 880 microscope (Zeiss, 
Oberkochen, Germany) with AiryScan at 63×/1.4NA. The optical resolution of the captured 






Fractionation of serum samples by high-performance liquid chromatography (HPLC) 
IgG was depleted from heat-inactivated serum as previously described by binding IgG in 
serum to a protein G column and collecting the IgG depleted flow through (30) . The IgG-
depleted serum samples were fractionated by HPLC using a Superdex 200 10/300 GL column 
(GE Healthcare, Piscataway, NJ) and the AKTA Purifier system. Proteins were eluted 
isocratically at a flow rate of 0.5 mL/min in 1X PBS. Absorbance was monitored at 220 and 280 
nm and fractions were collected in a 96-well plate with 1 min of interval.  
 
Liquid chromatography/mass spectroscopy (LC/MS) of serum 
Active fractions (B11 and C3) and inactive, lateral fractions (B9, C1 and C5) from 
Superdex 200 chromatography were submitted for protein identification by LC/MS at the 
Research Technology Branch Core Facility of the NIAID. Mass spectrometry was performed on 
reduced and alkylated, trypsin digested samples prepared by standard mass spectrometry 
protocols. The supernatant and two washes (5% formic acid in 50% acetonitrile) of the gel 
digests were pooled and concentrated with a Speed Vac (Labconco, Kansas, MO) to dryness 
directly in 200 µl polypropylene auto-sampler vials (Sun Sri, Rockwood, TN). The peptides were 
re-suspended in 10 µl of Solvent A (98% water; 2% acetonitrile; 0.1% formic acid) prior to mass 
spectrometry acquisitions. Samples were acquired on an Orbitrap Fusion Tribrid mass 
spectrometer (ThermoFisher Scientific, San Jose, CA) equipped with an EASY-Spray Ion Source 
and an Easy-nLC 1000. The nano-LC was carried out on an ES0802 analytical column (2µm/75 
µm /25 cm) at 60C and a PepMap C18 Trap column operating a linear gradient over 80 mins 
from 100% mobile phase A to 40% mobile phase B (98% acetonitrile;2% water;0.1% formic 
acid), a ramp to 80% B over 2 mins and a final hold at this concentration for additional 2 mins. 
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Acquisitions were performed in data dependent mode with a cycle time of 3 secs with a full MS 
scan of all ions from m/z 400 to mz/ 1800 at a resolution of 120,000 (m/z 190 at the target value 
of 4E5). The most intense precursor ions were fragmented in the Ion Trap using an isolation 
window of 1 m/z, a q of 0.25, and CID collision energy of 35%. Dynamic exclusion was enabled 
with the duration of 15 sec with ± 10 ppm mass tolerance. Raw files were searched using 
PEAKS v8.5 (BSi, Waterloo, Canada) against a Uniprot KB database containing Human, Pig and 
Cow proteins (02/2018) and common contaminants (cRAP.fasta, theGPM.org). Peptides were 
filtered at a 0.5% peptide FDR with a 2 peptide per protein minimum. Quantitation was 
performed using a Top 3 approach. 
 
Recombinant protein analyses  
Recombinant PfEMP1 proteins were produced in baculovirus-infected insect cells as 
previously described (29, 63, 65). Newly designed N-terminal “head-structure” proteins spanned 
from start 1-Methionine to a 728-Cysteine (~85 kDa) of the PFD1235w variant and from 1-
Methionine to 724-Cysteine 724 (~84 kDa) of the IT4var20 variant. 
Proteins were treated with 50 nM (4 µg/mL) C1s in 1:1 molar ratio for 1 hr and analyzed 
by SDS PAGE. Analysis of recombinant PfEMP1 protein binding to human receptors, 
endothelial protein C receptor (63), ICAM-1 (64) and CD36 was performed using ELISA as 
previously described (29, 65, 66). In short, ELISA plates were coated either with human receptor 
(3 µg/mL) or recombinant PfEMP1 (5, 15 or 30 µg/mL for single domains, head structure or full 
length ectodomian PfEMP1 proteins, respectively). After blocking, coated proteins were 
incubated with recombinant PfEMP1 or human receptor at said concentrations for 1 hr. Human 
receptors were detected using HRP-conjugated streptavidin and recombinant PfEMP1 proteins 
  21
were detected using HRP-conjugated anti-V5 tag antibodies. All analyses were performed in 
duplicates. 
 
Liquid chromatography–mass spectrometry and N-terminal protein sequencing of C1s 
cleaved PfEMP1 protein 
C1s cleavage products of IT4var13 and IT4var20 were excised from SDS page gels, 
subjected to in-gel tryptic digestion and analyzed by reverse phase liquid chromatography and 
Shotgun Mass-Spectrometry. In-gel digested peptides were loaded onto a 15 cm x 75 µm 
PepMap™RSLC column packed with 2 µm C18 beads (ES803A; Thermo Fisher Scientific, San 
Jose, CA), using EASY-nLC 1200 chromatography system with a 2 cm x 75 µm, 
Acclaim®PepMap100 trap column, packed with 3 µm, C18 beads. The peptides were eluted 
from the column in a mixture of Solvent A (0.1% Formic Acid (LS118-212; Fisher Scientific, 
Hampton, NH) and Solvent B (80% Acetonitrile, 0.1% Formic Acid (15431423; Fisher 
Scientific, Hampton, NH) at 250 nL/min rate. The chromatographic gradient was from 6% to 
60% Solvent B in 45 mins (from 6% to 23% in 20 mins; from 23% to 38% in 10 mins; from 38% 
to 60% in 3 mins; followed by wash steps from 60% to 95% in 5 mins and 95% Solvent B for 7 
mins). Shotgun MS was performed using a Q Exactive Mass spectrometer (Thermo Fisher 
Scientific, San Jose, CA) operated in data-dependent acquisition mode for 70min. MS1 
resolution of 70.000, AGC target set to 3e6, maximum injection time set to 20 ms, scan range 
300 to 1750 m/z, selecting the Top 10 MS1 ions for MS2 analysis. MS2 scans used 17,500 
resolution, AGC target of 1e6, maximum injection time 60ms, and isolation window of 1.6 m/z 
at normalized collision energy of 25. Minimum AGC target was set to 1e3 and dynamic 
exclusion at 30 s. MS data analysis was performed using Proteome Discoverer 2.4, searching the 
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IT4var20 and IT4var13 sequences. The database was concatenated with one composed of all 
protein sequences in reversed order. We applied 10 ppm precursor ion tolerance for total protein 
level identification and 0.02 Da for fragment ion tolerance using SEQUEST search algorithm 
and Percolator for FDR filtering. Carbamidomethylation of cysteine residues (+57.021 Da) was 
set as a static modification, while Oxidation (+15.995 Da) was set as a variable modification. 
Peptide-spectrum matches (PSM’s) did not exceed 1% false discovery rate (FDR). Filtered 
PSM’s were further filtered for peptide and protein-level FDR of 1%. Data output is given in 
Dataset S2. 
For Edman N-terminal sequencing, C1s-treated IT4var20 ectodomain was dissolved in 
LDS buffer with DTT and heated at 70C for 10 mins. The sample was loaded onto the NuPAGE 
12% Bis-Tris gel and separated with MOPS running buffer at 200V for 50 mins. The gel was 
blotted onto a PVDF membrane and stained with Ponceau. The ~95 kDa band of interest was cut 
out and analyzed by N-terminal Edman sequencing of five residues using an ABI Procise 494 
sequencer. Raw data can be found in Dataset S2.  
 
Bioinformatic analyses 
PfEMP1 interdomain sequences were extracted from domain-annotated PfEMP1 protein 
sequences of 15 P. falciparum genomes assembled from PacBio long-read-sequencing data 
ftp.sanger.ac.uk/pub/project/pathogens/Plasmodium/falciparum/PF3K/ (44). Reoccurring protein 
sequence motifs in the interdomain sequences were identified using MEME, meme-
suite.org/meme/tools/meme (45), by searching for the 32 most abundant motifs of minimum four 
residues in length. The Position-Specific Scoring Matrix (PSSM) for each of two identified C1s-
like motifs (MEME1 and MEME2) are given in Dataset S2 and formatted ready for use in 
MEME (https://meme-suite.org/meme/). As such they can be used to identify putative C1s-
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cleavage sites in any PfEMP1 sequence e.g., using the MEME “Find Individual Motif 
Occurrences” FIMO function. These were used for mapping C1s-like sites back on onto full-
length PfEMP1 sequences. Figure 5 shows C1s site positions in 275 representative domain 
annotated PfEMP1 sequences. 
 
Statistical analysis 
All data were statistically analyzed and graphed using GraphPad Prism 8. Data are 
presented as mean  SEM. Data were log transformed and an unpaired two-tailed T-test was 
performed to compare groups to the positive binding control. For comparison of the eight 
potential candidates to control (Fig. 1C), an ordinary one-way ANOVA was performed with 
Dunnett’s test.  
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Figure 1. Serum fractions B11 and C3 inhibit IT4var19 IE binding to brain endothelial 
cells. (A) Chromatographic fractionation of serum by size-exclusion chromatography. IgG-
depleted serum was run on a Superdex 200 Increase 10/300 GL column. Protein fractions were 
eluted using a linear gradient and the absorbance (mAbs) monitored at 280 nm. The arrows show 
the binding inhibitory fractions B11 and C3. (B) Binding of IT4var19 IEs to HBEC-5i in binding 
medium with 10% human serum, IgG-depleted human serum, or serum fractions (A6-C6). A no 
serum control was included. Each data point is from two independent experiments done in 
duplicate and the mean and SEM are shown for each fraction. Fractions B11 and C3 most 
affected the binding. These fractions were run on MS/MS and the components were run to 
determine their effect on binding as shown in (C) to identify potential inhibitors for binding. (C) 
Binding of IT4var19 IEs to HBEC-5i in binding medium with proteins identified by MS/MS in 
the serum inhibitory B11 and C3 fractions (attractin, C1s, C4b, factor H, IgD, IT1H1, ITIH2 and 
kappa light chain). Data are mean  SEM, and each data point is from an independent 
experiment. ** P<0.01; *** P<0.001. 
 
Figure 2. C1s inhibits binding of IT4var19 IEs to EPCR but does not reverse binding of 
bound IEs. (A) Binding of IT4var19 IEs to EPCR in the absence or presence of C1s (0.03 
g/mL – 30 g/mL). (B) No evidence of the reversal of IT4var19 IEs bound to EPCR in the 
presence of C1s (30 g/mL – 100 g/mL). The mean and SEM are shown, and each data point is 
from an independent experiment. All mean values were log-transformed, and a two-tailed 
unpaired t-test was conducted to compare C1s treated groups to the positive control (EPCR 
only). ** P<0.01; *** P<0.001.  
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Figure 3. C1s cleaves the native PfEMP1 on the surface of IT4var19 IEs. Staining of (A) 
IT4var19 IEs, (B) C1s treated IT4var19 IEs, (C) FCR3 (VAR2CSA) and (D) C1s-treated FCR3 
(VAR2CSA) with rabbit polyclonal IgG to IT4var19 NTS.DBLα or rat polyclonal IgG to FCR3 
full length VAR2CSA. IEs were identified by DAPI staining of parasite nuclei (blue). IT4var19 
PfEMP1 staining of the IEs is shown in green and FCR3 VAR2CSA PfEMP1 staining is shown 
in red.  
 
Figure 4. C1s inhibits binding of IT4var20 IE to EPCR and IT4var13 IE binding to CD36 
but not ICAM-1. (A) Binding of IT4var20 IEs to EPCR in the absence or presence of C1s (100 
g/mL). Recombinant EPCR (rEPCR) was included as a control and indicator of how well C1s 
treatment abrogated IT4var20 binding to EPCR. (B) Binding of IT4var13 IEs to CD36 or ICAM-
1 in the absence or presence of C1s (100 g/mL). In both binding assays, bovine serum albumin 
(BSA) was included as a negative control. The mean and SEM are shown, and each data point is 
from an independent experiment. For statistical testing, all mean values were log-transformed, 
and a two-tailed unpaired t-test was conducted to compare experimental groups to the positive 
control (EPCR only).  (C) Var gene transcript levels relative to the housekeeping control gene, 
seryl-t-transferase, confirming the major var types being expressed as IT4var20 and IT4var13. * 
P<0.05; ** P<0.01; ns – not significant. 
 
Figure 5. Analysis of observed and predicted C1s cleavage sites in PfEMP1.  
(A) SDS page showing C1s cleaves the full-length recombinant ectodomains of IT4var13 and 
IT4var20 PfEMP1 into two major bands (arrows, numbered 1 to 4). (B) Protein schematics of the 
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IT4var13 and IT4var20 ectodomains showing the C1s cleavage products (black arrows, above 
the protein schematic from panel (A). The boxed insets show the interdomain sequences where 
C1s cleavage sites were identified in IT4var13 and IT4var20 by LS/MS and N-terminal protein 
sequencing analyses. C1s cleaves at one site in IT4var13 and three sites in IT4var20 (red arrows) 
at residues (large amino acid letters) resembling C1s-motifs.  Of the four C1s-like sequence 
motifs found in IT4var20, three (red arrows) in (B) were experimentally confirmed and the 
fourth site (green arrow) in panel (B) may also have been cleaved but could not be validated due 
to its presence in a small peptide product lost in gel-electrophoresis. (C) C1s cleavage sites in 
PfEMP1 resemble previously identified semi-conserved sequence motifs, known as homology 
blocks HB49, HB134 and HB241(11), found in the otherwise low sequence complexity 
interdomain regions of PfEMP1. (D) Reanalysis of conserved sequence motifs in PfEMP1 
interdomains from 15 long-read sequenced P. falciparum genomes using MEME confirms the 
presence of C1s-like cleavage motifs (sequence LOGOs shown at left). The right side shows 275 
representative full-length PfEMP1 from 15 PacBio long-read sequenced P. falciparum genomes 
(44). The different PfEMP1 are stacked from top to bottom in three columns and aligned by their 
domain composition (not scaled to sequence length). Each domain type is color-coded and white 
gaps between domains represent interdomain regions, which may vary from 10 to 225 amino 
acids in length. Interdomain regions containing one or more predicted C1s-like cleavage sites 
(MEMEs 1 and 2) are indicated by red crosses. NTS = N-terminal segment at the beginning of 
protein, ATS = acidic terminal segment or cytoplasmic tail.  
 
Figure 6. Analysis of C1s-treated recombinant PfEMP1. (A) SDS page gel showing two 
representative PfEMP1 CIDR domains (EPCR-binding IT4var19 CIDRα1 and CD36-binding 
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CIDRα3) and two EPCR-binding head-structure domain complexes (PFD1235w [NTSA-
DBLα1-CIDRα1] and IT4var20 [NTSA-DBLα1-CIDRα1]) before and after treatment with 50 
nM C1s at 1:1 molar ratio for 1 hr at 37˚C. No proteolysis was seen. (B) ELISA data showing the 
effect of 50 nM C1s pre-treatment on binding of recombinant PfEMP1 proteins to coated EPCR, 
CD36 or ICAM-1 (filled boxes) versus EPCR binding to coated recombinant PfEMP1 (hashed 
boxes). Whereas C1s treatment reduced binding activity of full length PfEMP1 ectodomains, 
recombinant PfEMP1 head structure domains are insensitive to C1s treatment, indicating that 
C1s cleavage sites are located in the interdomain regions, consistent with mass spectrometry 
analysis. As a control, C1s treatment of EPCR did not affect its binding to full-length PfEMP1 
ectodomains (hashed boxes). 
 
Table legends. 




































IT4var19 Yes EPCR Yes Yes *** ND 
IT4var20 Yes EPCR Yes Yes * Yes 
3D7 
MAL6P1.316 
Yes EPCR Yes Yes * ND 
3173-S ND
a
 EPCR ND Yes
#




CD36 Yes Yes ** 
Yes 




CD36 No No ns 
ND 




CD36 No No ns 
ND 
ICAM-1 No No ns 
P6G2 
(IT4var31) 
No CD36 No No ns ND 
P2E11 
(IT4var33) 
Yes CD36 Yes Yes ** ND 
P6D12 
(IT4var39/67) 
Yes CD36 Yes Yes ** ND 
FCR3 
(VAR2CSA) 
No CSA No No ns ND 
* p<0.05, ** p<0.01; *** p<0.001 
ns – not significant 
ND – Not determined 
a
 – Full sequence not available yet for prediction. Partial Sequence available – GenBank: 
QBH72553.1 
b
 – predicted cleavage between CD36 and ICAM-1 binding domains 
# 
- binding assay conducted with HBEC-5i. 
 
 
